Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,803Revenue (TTM) $M30.6Net Margin (%)-685.9Altman Z-Score0.7
Enterprise Value $M1,685EPS (TTM) $-0.8Operating Margin %-680.5Piotroski F-Score1
P/E(ttm)--Beneish M-Score-6.9Pre-tax Margin (%)-685.9Higher ROA y-yN
Price/Book9.710-y EBITDA Growth Rate %2.5Quick Ratio6.8Cash flow > EarningsY
Price/Sales58.45-y EBITDA Growth Rate %17.2Current Ratio6.8Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-46.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-64.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M271ROIC % (ttm)-294.0Gross Margin Increase y-yN

Gurus Latest Trades with NVAX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVAXGeorge Soros 2016-03-31 Buy $4.36 - $8.39
($5.42)
$ 6.6623%New holding30,300
NVAXJoel Greenblatt 2015-12-31 Sold Out -0.01%$6.59 - $8.77
($7.73)
$ 6.66-14%Sold Out0
NVAXJoel Greenblatt 2015-09-30 Buy 0.01%$6.41 - $14.14
($11.21)
$ 6.66-41%New holding110,640
NVAXFirst Eagle Investment 2014-12-31 Sold Out -0.0052%$4.05 - $5.98
($5.25)
$ 6.6627%Sold Out0
NVAXFirst Eagle Investment 2014-06-30 Add$3.69 - $5.13
($4.39)
$ 6.6652%Add 150.00%500,000
NVAXDavid Swensen 2014-03-31 Sold Out -0.23%$4.13 - $6.65
($5.59)
$ 6.6619%Sold Out0
NVAXFirst Eagle Investment 2014-03-31 Reduce-0.01%$4.13 - $6.65
($5.59)
$ 6.6619%Reduce -75.00%200,000
NVAXDavid Swensen 2013-12-31 Buy 0.23%$2.76 - $5.16
($3.51)
$ 6.6690%New holding25,398
NVAXGeorge Soros 2013-12-31 Sold Out -0.02%$2.76 - $5.16
($3.51)
$ 6.6690%Sold Out0
NVAXGeorge Soros 2013-09-30 Buy 0.02%$2.25 - $3.39
($2.82)
$ 6.66136%New holding573,000
NVAXFirst Eagle Investment 2013-09-30 Buy 0.01%$2.25 - $3.39
($2.82)
$ 6.66136%New holding800,000
NVAXFirst Eagle Investment 2011-03-31 Sold Out $2.15 - $2.96
($2.44)
$ 6.66173%Sold Out0
NVAXFirst Eagle Investment 2010-09-30 Add$2.01 - $2.34
($2.2)
$ 6.66203%Add 25.00%125,000
NVAXFirst Eagle Investment 2010-06-30 Reduce$2.18 - $2.97
($2.46)
$ 6.66171%Reduce -52.65%100,000
NVAXFirst Eagle Investment 2009-12-31 Buy 0.01%$2.53 - $4.41
($3.46)
$ 6.6692%New holding250,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVAX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
EVANS GARY CDirector 2016-06-06Sell18,998$6.52.46view
EVANS GARY CDirector 2016-05-24Sell50,000$5.4123.11view
Erck Stanley CPresident and CEO 2016-03-31Sell424,778$5.1928.32view
Trizzino JohnSVP, Commercial Operations 2016-01-31Buy5,855$3.6383.47view
Herrmann John A IIISVP, General Counsel 2016-01-31Buy2,072$4.3852.05view
Glenn Gregory MSVP, Research and Development 2016-01-31Buy2,369$4.3852.05view
PHILLIPS BARCLAY ASVP, CFO 2016-01-31Buy405$4.3852.05view
Erck Stanley CCEO and President 2016-01-31Buy2,072$4.3852.05view
Glenn Gregory MSVP, Research and Development 2015-12-16Sell61,886$8.58-22.38view
Herrmann John A IIISVP, General Counsel 2015-12-16Sell27,945$8.64-22.92view

Quarterly/Annual Reports about NVAX:

News about NVAX:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: United States Steel Corp, Tuesday Morning Corp, Novavax Inc. Feb 08 2015 
Novavax Inc. Reports Operating Results (10-Q) Nov 08 2010 
Novavax Inc. Reports Operating Results (10-Q) Aug 06 2010 
Novavax Inc. Reports Operating Results (10-Q) May 10 2010 
Novavax Inc. Reports Operating Results (10-Q) Nov 09 2009 
Novavax Inc. Reports Operating Results (10-Q) Aug 10 2009 
Novavax Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
4 Red-Hot Biotech Stocks With Over 100% Upside Potential Jun 21 2016
Novavax Recognized by Washington Post as Top Workplace - Jun 17 2016
Novavax Recognized by Washington Post as Top Workplace Jun 17 2016
NOVAVAX INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 10 2016
Bullish Chart Patterns For These Four Momentum Stocks Jun 09 2016
Research Coverage Scans Stocks on the Biotechnology Industry for Today Jun 08 2016
2 Analyst Biotech Stock Calls With Over 100% Upside Potential Jun 06 2016
Trending Now: NVAX Jun 02 2016
Novavax Announces New Seasonal Combination Respiratory Vaccine Program - Jun 02 2016
Novavax Announces New Seasonal Combination Respiratory Vaccine Program Jun 02 2016
What's behind put action in Novavax Jun 02 2016
Why Novavax, Inc. (NVAX)’s Shares Are Trading in Green on Wednesday? May 25 2016
Will Novavax pull back later this year? May 25 2016
U.S. FDA Grants Fast Track Designation to Novavax’ RSV F Vaccine for Older Adults - May 25 2016
U.S. FDA Grants Fast Track Designation to Novavax' RSV F Vaccine for Older Adults - May 25 2016
U.S. FDA Grants Fast Track Designation to Novavax’ RSV F Vaccine for Older Adults May 25 2016
ETF’s with exposure to Novavax, Inc. : May 24, 2016 May 24 2016
[$$] Four Biotech Picks With 2016 Catalysts May 23 2016
Novavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : May 23, 2016 May 23 2016
Novavax Receives the Tech Council of Maryland’s Chairman’s Award - May 12 2016
Novavax Receives the Tech Council of Maryland's Chairman's Award - May 12 2016
Novavax to Participate in the 2016 Citi Midwest Healthcare Access Day - May 11 2016
Novavax reports 1Q loss May 04 2016
Novavax Reports First Quarter 2016 Financial Results - May 04 2016
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 4, 2016 - Apr 27 2016
Novavax to Participate in the FBR New Prescriptions Conference - Apr 13 2016
Novavax to Present at the 15th Annual Needham Healthcare Conference - Apr 06 2016
Novavax, Inc. : Novavax Announces Management Promotion - Apr 04 2016
Novavax Announces Management Promotion - Apr 04 2016
Novavax reports 4Q loss Feb 29 2016
Novavax Announces Closing of $300 Million Offering of Convertible Senior Notes Due 2023 - Jan 29 2016
Novavax Prices $300 Million of Convertible Senior Notes Due 2023 - Jan 25 2016
Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023 - Jan 25 2016
Novavax Appoints Jeffrey Stoddard, M.D., Vice President, Medical Affairs - Jan 08 2016
Novavax to Present at the 34th Annual J.P. Morgan Healthcare Conference - Jan 06 2016
Novavax Appoints Mark Twyman Vice President Marketing - Dec 21 2015
Novavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults - Dec 14 2015
Novavax reports 3Q loss Nov 09 2015
Novavax reports 2Q loss Aug 10 2015
Novavax: Early study indicates its vaccine effective vs. RSV Aug 10 2015
Novavax reports 4Q loss Feb 27 2015
Novavax meets 3Q profit forecasts Nov 06 2014

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)